These findings indicate that CD26high T cells are a potential target for immunomodulatory MS treatments, and in a previous study we found that the number of circulating T cells, especially CD4+CD26+ T cells, predicted relapses in MS patients treated with IFN-β [22]. The gene discussed is CD4; the disease is myeloid sarcoma.